See package insert. How to take and store Felbamate? Follow your doctor’s directions. Call if you have any questions. Usually, your doctor will tell you to start by. Felbatol is the brand name used in the United States for felbamate. Read the black box warning in the Package Insert to your patient and obtain any necessary . Felbamate, also known as Felbatol, has been approved by the Food and Drug about all potential risks before using this drug and read the package insert.

Author: Malakinos Zulkisar
Country: Gabon
Language: English (Spanish)
Genre: Personal Growth
Published (Last): 4 May 2016
Pages: 137
PDF File Size: 11.51 Mb
ePub File Size: 20.73 Mb
ISBN: 595-4-46424-289-1
Downloads: 44964
Price: Free* [*Free Regsitration Required]
Uploader: Mikalabar

The plasma half-life of felbamate is 13—23 hours and is not changed after multiple doses.

Decreased serum concentrations of vorapaxar and thus decreased efficacy are possible when vorapaxar, a CYP3A4 substrate, is coadministered with felbamate, a mild CYP3A inducer. Additionally, patients taking non-oral combination contraceptives or estrogens or progestins for hormone replacement therapy may also experience reduced clinical efficacy; dosage adjustments may be necessary.

Your Name Your name is required. packave

If seizures occur, amphetamine discontinuation may be necessary. Hydroxychloroquine can lower the seizure threshold; therefore, the activity of antiepileptic drugs may be impaired with concomitant use. Used for partial seizures in adults and Lennox-Gastaut syndrome in children and adults. Serum concentrations of other anticonvulsants should be obtained and dosage adjustments made as necessary.

Atropine; Hyoscyamine; Phenobarbital; Scopolamine: Moderate Concurrent use of topiramate and drugs that cause thrombocytopenia such as the anticonvulsant felbamate may increase the risk of bleeding. A baseline CBC with platelets and reticulocytes should be obtained, as well as routine laboratory monitoring throughout treatment.


PDR Search

Concurrent use may decrease the plasma concentrations of elvitegravir, leading to a reduction of antiretroviral efficacy and the potential development of viral resistance. When an anticonvulsant is being used to manage behavior, stabilize mood, or treat a psychiatric disorder, the facility should attempt periodic tapering of the medication or provide documentation of medical necessity in accordance with OBRA guidelines. In Septemberthe manufacturer issued a letter stating 8 cases of acute hepatic failure, including 4 deaths, were associated with the use of inesrt.

If use together is necessary, obtain an ECG prior to lacosamide initiation and after treatment has been titrated to steady-state. Major Maprotiline, when used concomitantly with anticonvulsants, can increase CNS depression and may also lower the seizure threshold, leading to pharmacodynamic insery. Major Avoid concurrent use of dolutegravir with felbamate, as coadministration may result in decreased dolutegravir plasma concentrations.

In those with psckage bleeding packafe, patients were often taking drugs that inswrt thrombocytopenia or affect platelet function or coagulation. Patients and caregivers should be informed of the increased risk of suicidal thoughts and behaviors and should be advised to immediately report the emergence or worsening of depression, the emergence of suicidal thoughts or behavior, thoughts of self-harm, or other unusual changes in mood or behavior.

Monitor patients for adverse reactions and breakthrough fungal infections if these drugs are coadministered. Major Avoid concurrent use of felbamate with bedaquiline. Alternatives to clarithromycin should be considered in patients who are taking CYP3A4 inducers. Felbamate is contraindicated in patients with a history of any hematological disease e.


Felbatol (felbamate) dose, indications, adverse effects, interactions from

Moderate Concurrent administration of felbamate and other antiepileptic drugs results in changes in serum concentrations of both felbamate and the antiepileptic drugs. The intended therapeutic effect of clarithromycin could be decreased. Guidance is not available regarding concomitant use of cobimetinib with weak CYP3A inducers. According to the manufacturer, felbamate is excreted into breast milk, but its effects on the infant are unknown.

Felbamate is a CYP3A4 inducer, which may result in decreased bedaquiline systemic exposure AUC and possibly reduced therapeutic effect. Felbamate should only be used in patients with epilepsy that is so severe that the risk of aplastic anemia is acceptable in accordance with the benefits associated with felbamate use. We do not record any personal information entered above. Felbamate is administered orally.

For storage information, see specific product information within the How Supplied section. It is not known if the duration of felbamate exposure or the dose used influences the risk for aplastic anemia. Patients must call to enroll in the registry.

Prior to this request, preliminary evidence had suggested a possible link between anticonvulsant use and suicidality. Agents that induce CYP3A4 may increase the metabolism of vincristine and decrease the efficacy of drug, including felbamate.

Affected cytochrome P isoenzymes: While the OH-clarithromycin active metabolite concentrations are increased, this metabolite has different antimicrobial activity compared to clarithromycin.